192 related articles for article (PubMed ID: 36685530)
1. CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis.
Li J; Li H; Wang Y; Zhao X; Wang S; Li L
Front Immunol; 2022; 13():1071219. PubMed ID: 36685530
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of 28 cases of anti
Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of anti-leucine-rich glioma-inactivated 1 encephalitis in northeast China.
Zhao Q; Sun L; Zhao D; Chen Y; Li M; Lu Y; Li G; Lin W
Clin Neurol Neurosurg; 2021 Apr; 203():106542. PubMed ID: 33706063
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2.
Murayama A; Sugaya K; Hara M; Kawazoe T; Tobisawa S; Nakajima H; Takahashi K
Intern Med; 2023 Jun; 62(11):1659-1663. PubMed ID: 36223927
[TBL] [Abstract][Full Text] [Related]
5. A case of pediatric anti-leucine-rich glioma inactivated 1 encephalitis with faciobrachial dystonic seizure.
Jang S; Kim SY; Kim WJ; Chae JH; Kim KJ; Lim BC
Brain Dev; 2023 Jun; 45(6):348-353. PubMed ID: 36858863
[TBL] [Abstract][Full Text] [Related]
6. [Clinical analysis of 9 cases with Anti-leucine-rich glioma inactivated 1 protein antibody associated limbic encephalitis].
Zhang YX; Yang HL; Wu YY; Wang CC; Gao XY; Shi YY; Liu HQ; Huang Y; Zhang JW
Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1295-1298. PubMed ID: 28482428
[No Abstract] [Full Text] [Related]
7. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis].
Li JM; Ma XR; Peng T; Li JH; Lu H
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594
[No Abstract] [Full Text] [Related]
9. Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis.
Zhao J; Wang C; Zhang Y; Sun R; Wang H; Li G; Zhang J
J Neuroimmunol; 2019 Sep; 334():577005. PubMed ID: 31310926
[TBL] [Abstract][Full Text] [Related]
10. What Is Different about Teratoma-Associated Anti-LGI1 Encephalitis? A Long-Term Clinical and Neuroimaging Case Series.
Li C; Cai HB; Zhao X; Xi XC; Zhou Q; Luo HY; Tang ZP; Kang HC; Kirsch HE
Eur Neurol; 2022; 85(6):437-445. PubMed ID: 35896086
[TBL] [Abstract][Full Text] [Related]
11. A Case of Anti-Leucine-Rich Glioma-Inactivated Protein 1 (Anti-LGI1) Limbic Encephalitis With New-Onset Panic Attacks.
Coleman B; Sawhney K; LaPenna P
Cureus; 2024 Apr; 16(4):e58406. PubMed ID: 38756253
[TBL] [Abstract][Full Text] [Related]
12. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study.
Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J;
Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune encephalitis related to LGI1 antibodies with negative MRI study: Description of two cases.
Lian X; Zheng K; Chen W; Li D; Xue F; Wang G
Med Clin (Barc); 2024 Jan; 162(1):35-38. PubMed ID: 37517931
[TBL] [Abstract][Full Text] [Related]
14. CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study.
Nissen MS; Ryding M; Nilsson AC; Madsen JS; Olsen DA; Halekoh U; Lydolph M; Illes Z; Blaabjerg M
Front Immunol; 2021; 12():719432. PubMed ID: 34975832
[TBL] [Abstract][Full Text] [Related]
15. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
Huang X; Fan C; Gao L; Li L; Ye J; Shen H
J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
[TBL] [Abstract][Full Text] [Related]
16. Predicting the functional outcomes of anti-LGI1 encephalitis using a random forest model.
Li G; Liu X; Wang M; Yu T; Ren J; Wang Q
Acta Neurol Scand; 2022 Aug; 146(2):137-143. PubMed ID: 35373330
[TBL] [Abstract][Full Text] [Related]
17. Agrypnia excitata as the main feature in anti-leucine-rich glioma-inactivated 1 encephalitis: a detailed clinical and polysomnographic semiological analysis.
Piffer S; Cantalupo G; Filipponi S; Poretto V; Pellegrini M; Tanel R; Buganza M; Giometto B
Eur J Neurol; 2022 Mar; 29(3):890-894. PubMed ID: 34679240
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune parkinsonism with faciobrachiocrural dystonic seizures: a new phenotype of leucine-rich glioma-inactivated 1 (LGI1) autoimmunity.
Sasikumar S; Vincent J; Gopinath S; Nambiar V; Umesh SU; Kannoth S; Antony D; Mathai A; Anandakuttan A
Acta Neurol Belg; 2022 Oct; 122(5):1323-1328. PubMed ID: 35851655
[TBL] [Abstract][Full Text] [Related]
19. Comparing clinical features, severity and prognosis of autoimmune encephalitis and with and without oligoclonal bands.
Xue H; Guo X; Jiang Y; Qin L; Wang X; Xu J; Zuo S; Liu Q; Li W
Front Neurol; 2023; 14():1281276. PubMed ID: 38249729
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
